Abstract Mitochondrial disorders are frequently encountered inherited diseases characterized by unexplained multisystem involvement with a chronic, intermittent, or progressive nature. The objective of this paper is to describe the profile of patients with mitochondrial disorders in South Africa. Patients with possible mitochondrial disorders were accessed over 10 years. Analyses for respiratory chain and pyruvate dehydrogenase complex enzymes were performed on muscle.
Introduction
Patients and parents of children with unexplained chronic disorders usually have a critical need to understand what is wrong and why they have the disorder. Smeitink (2003) concludes that a mitochondrial disorder should be considered in "every unexplained chronic, intermittent, or progressive disorder with single or multisystem involvement, even if the lactic acid is normal". With mitochondrial disorders now among the most frequently encountered inherited diseases, with a minimum prevalence of at least 1 in 5,000 affecting patients of all ages and mitochondrial encephalomyopathies affecting 1 in 21,000 children under the age of 16 years, it is crucial to have a center that is able to offer a comprehensive diagnostic service (Schaefer et al. 2004; Darin et al. 2001) . Although previously recognized, the prevalence of mitochondrial disorders in South Africa is still unknown. Diagnosis of these disorders is complicated and requires a combination of clinical, histochemical, and biochemical assessment of oxidative phosphorylation and other related functions, as well as molecular genetic studies. Although screening for a limited number of point mutations is available in SA, a comprehensive service has not been available to confirm diagnoses. Logistical issues further complicate diagnosis; for example, patients living in remote rural areas with no transport or means of communication readily available and the scattered and distant locations for clinical and biochemical evaluations. This paper reports on the clinical and biochemical findings in South African patients obtained during a 10-year study on these disorders.
Methods

Ethical considerations
Ethical approval for the study was obtained from the University of Pretoria (No. 91/98 and amendments) and from the North-West University (02M02). Informed consent was obtained from the parents of patients and controls.
Patients
Patients with neuromuscular disorders, mostly children, were assessed at the Paediatric Neurology Unit at Steve Biko Academic Hospital, Pretoria, South Africa, which provides services for urban and rural communities. The area from which the majority of the patients were referred has 5.9 million children under the age of 15 years and primarily encompasses three provinces: Gauteng, Mpumalanga, and Limpopo (Statistics South Africa 2009). Assessment included a detailed history; clinical examination; baseline investigations, including lactate (L), pyruvate (P), creatine kinase (CK), and ammonia (NH 3 ); and appropriate patientspecific investigations according to clinical findings. A computed tomography (CT) scan or magnetic resonance imaging (MRI) of the brain was performed in cases in which the patient had clinical features of central nervous system (CNS) involvement. Nerve conduction studies (NCS) and electromyography (EMG) were performed in cases in which a neuropathy or myopathy was suspected. Brainstem auditory-evoked responses (BAER) and visualevoked potentials (VEP) were requested in cases in which the patient had clinical hearing or visual impairment. Electrocardiography (ECG) and cardiac sonography were performed, and a chest X-ray (CXR) was taken in cases in which the patient had cardiomegaly, cardiac murmurs, or irregular pulses. The Mitochondrial Disease Criteria (MDC) score was calculated for every patient (Wolf and Smeitink 2002) . Muscle biopsies on vastus lateralis muscle were performed on patients with an MDC score of six and higher or in cases in which the patient had a specific phenotype suggestive of a mitochondrial etiology. A total of 191 patients with possible mitochondrial disorders were assessed from 1999 until June 2009, and a total of 140 muscle biopsies were analysed, including 24 controls.
Biochemical analyses
Metabolic analyses of urine samples included analyses of amino acids (AA), organic acids (OA), acylcarnitines (AC), and oligosaccharides (OS) (Jooste et al. 1994; Loots et al. 2007; Sewell 2008; Van Rooyen et al. 1994) . Mitochondrial respiratory chain (RC) enzymes (CI-IV; EC 1.6.5.3, EC 1.3.5.1, EC 1.10.2.2, EC 1.9.3.1, respectively), pyruvate dehydrogenase complex (PDHc, EC 1.2.4.1), and citrate synthase (CS, EC 2.3.3.1) activities were measured in muscle, essentially as described by Rahman et al. (1996) , Janssen et al. (2007) , and Shepherd and Garland (1969) . PDHc activity reported in this paper was measured using the pyruvate dehydrogenase (PDH) Enzyme Activity Dipstick Assay Kit (MitoSciences®, Eugene, OR, USA). Analyses were performed using 600 x g supernatants that were prepared from homogenizing frozen muscle samples in an isotonic buffer [mannitol 210 mM; sucrose 70 mM; 4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid (HEPES) 5 mM; ethylene glycol tetraacetic acid (EGTA) 0.1 mM; pH 7.2). Reference values for enzyme activities, normalized to CS, CII, and CIV activities, were developed using muscle samples obtained from healthy children, predominantly of ages 3-16 years, who were undergoing routine orthopedic surgery (n=24). With a limited number of controls, distribution of control values was estimated using the Transformation Kernel Density Estimation program (Sheather and Marron 1990) . A diagnosis of a mitochondrial disorder was made in cases where an enzyme deficiency was identified as follows: when an enzyme activity was lower than reference values when expressed against at least two of three enzyme markers (CS, CII, or CIV), providing that these were not deficient.
Data analyses
Biochemical data distributions of control values were measured as described in the previous section. A Jaccard cluster analysis was performed on the clinical and biochemical data using Bionumerics version 5 (Applied Maths). Fig. 1 , 21 patients (33.3%) presented with symptoms after the first year of life, nine (14.3%) between 1 and 5 years, five (7.9%) between 6 and 10 years, five (7.9%) in the second decade of life, and one (1.6%) each in the third and fourth decades of life.
Results
Sixty
The main clinical manifestations of mitochondrial disorders are illustrated in Fig. 2 , and Table 1 summarizes the clinical and biochemical manifestations of the individual patients investigated. Muscle involvement, including hypotonia, weakness, exercise intolerance, and myalgia, was found in 55 of the 63 patients (87.3%). Thirty-seven of the 40 African patients (92.5%) presented with muscular involvement (Table 2 ; Fig. 3a ). The typical presentations of these patients (25 of 40; 62.5%) included varying degrees of myopathy accompanied by a myopathic face, high palate, triangular mouth, and scoliosis. Fourteen of these 25 patients (56.0%) also had ptosis and/or progressive external ophthalmoplegia. None of the Caucasian or patients of other ethnicities presented with this specific myopathic phenotype. Only four of the 20 Caucasian patients (20.0%) presented with predominant muscular symptoms. CNS involvement as the predominant symptom with or without muscular symptoms was the more common phenotype among Caucasian patients. It is interesting to observe that seven of the 20 (35.0%) older Caucasian patients presented with significant progressive myalgia and exercise intolerance (Table 2 ; Fig. 3b ). None of these seven patients had presented with any symptoms in the first 2 years of life, and four of the seven (57.1%) presented with symptoms in the second decade of life and later. Four of the 20 Caucasian patients (20.0%) had significant encephalopathy, and 12 (60.0%) had encephalomyopathy (Table 2 ; Fig. 3b ). Only three of the 40 African patients (7.5%) presented with predominant CNS involvement, and 12 (30.0%) presented with encephalomyopathy (Table 2 ; Fig. 3a) . The z-test for the difference between two proportions (Table 2 ) yielded a p value of 0.0018 for the difference between proportions of Africans and Caucasians and those of other ethnicities with myopathy, indicating that significantly more African patients had myopathy than Caucasian and other ethnicities. Ophthalmologic involvement was found in 28 of the 63 patients (44.4%). Symptoms included nonparalytic strabismus, external ophthalmoplegia, ptosis, and retinitis pigmentosa. None of the Caucasian patients presented with external ophthalmoplegia or ptosis, but 17 of the 22 African patients with ophthalmologic involvement (77.3%) had external ophthalmoplegia and/or ptosis. Five of the 63 (7.9%) patients had hearing impairment and ten (15.9%) had neuropathy. Developmental delay was present in 41 of the 63 patients (65.0%), with 27 of the 40 African patients (67.5%) and 14 of the 23 Caucasian patients and patients of other ethnicities (60.1%). Thirteen patients (20.6%) experienced developmental regression.
Thirteen of the 63 (20.6%) patients had renal involvement ranging from asymptomatic aminoaciduria to rickets and de Toni-Debré-Fanconi syndrome. Gastrointestinal symptom was dysmotility and was found in five (7.9%). Failure to thrive was documented in 14 (22.2%) and hepatomegaly or deranged liver functions were in 11 (17.5%). A detailed family history was present in 17 (27.0%). Only four patients (6.3%) had documented cardiac involvement; nine (14.3%) had minor dysmorphisms; ten (15.9%) had skeletal involvement, including rickets and hypermobile joints, but scoliosis secondary to muscle weakness was excluded. Mean MDC score was 5.9. Lactic acidosis was found in 24 (38.1%) and a raised lactatepyruvate ratio (>18) in 14 (22.2%). Creatine kinase was raised in ten (15.9%) and ammonia in five (7.9%). Abnormal organic acid profiles with elevated Krebs's cycle metabolites and/or dicarboxylic acids were found in 24 (38.1%). No OA data was available for 14 of the 63 patients (22.2%). Abnormal amino acid profiles were found in 28 (44.4%) and amino acid data was unavailable for 14 (22.2%). Abnormal acylcarnitines were found in 22 (34.9%), and 27 (42.9%) had abnormal oligosaccharide profiles. Radiological changes were found in 34 (54.0%); nonspecific atrophy in 17; white matter involvement in 12; basal ganglia in five; cerebellar atrophy in five; absent or hypoplastic corpus callosum in two; and findings resembling recovered stroke episodes in two.
Thirteen African patients (32.5%) had single enzyme deficiencies, with four CI, one CII, six CIII, one CIV, and one PDHc. Complex I as a single deficiency was only found in four African patients (10.0%); 27 (68.0%) had combined deficiencies, with CI+III or CII+III involved in 21 of these (77.8%). Two African patients (5.0%) had PDHc combined with other RC deficiencies, and four (10.0%) had nonspecific combined RC deficiencies (Figs (Figs. 4 and 5b) . The z-test for the differences between two proportions yielded a p value of 0.0061 for the difference between the proportion of Africans and Caucasians and those of other ethnicities with CI+III or CII+III deficiencies, indicating that significantly more African patients had these deficiencies than Caucasians and other ethnicities. The Jaccard cluster analysis (Fig. 6 ) illustrated clearly that African patients tend to cluster together in terms of predominant myopathic involvement. It is also evident that a CII+III deficiency is mainly found in this group. It was also found in three Caucasian patients with exercise intolerance. However, no Caucasian patient with predominant CNS involvement was found in this group of deficiencies.
Discussion
To our knowledge, this study was the first in South Africa to characterize mitochondrial disorders clinically and biochemically in a group of patients over a period of 10 years. Screening for point mutations was not done routinely owing to the low yield of positive results and relative high cost. Although this study had many limitations, including the lack of genetic data, important logistic and procedural challenges were overcome, in addition to refinement of analyses and reference values. This resulted in an increased yield of positive results from 21.2% initially to 72.1%. 
Other ethnicity patients
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Different groups
Single enzyme deficiencies Combined enzyme deficiencies Using existing data and observing the age-matched population of the three provinces that form the source of this study, a prevalence of 1 per 100,000 children can be calculated. This value, however, is most likely an underestimation considering the strict inclusion criteria followed and the misdiagnosis or nondiagnosis of patients who were thus given no referral for further investigation. Although the number of patients with biochemically confirmed mitochondrial disorders reported in this study was limited to 63, and many aspects were in line with previous descriptions (Munnich et al. 1996; Munnich and Rustin 2001; Nissenkorn et al. 1999; Sciacco et al. 2001 ), important differences were observed. Of three recent studies with comparable data (Skladal et al. 2003a; Scaglia et al. 2004; Debray et al. 2007 ) our study, included the largest number of African patients (63.0%), with 31.7% Caucasian patients (Table 3) . The overall South African male:female ratio was comparable with other studies: 1.2:1 (Skladal et al. 2003a; Scaglia et al. 2004; Debray et al. 2007 ), but it is interesting to observe that the male:female ratio for African patients was 1:1.2, with females more affected. In the Austrian cohort, 41.3% of patients had early neonatal onset in contrast to only 33.0% of South African patients. African patients presented earlier than Caucasian patients. Population differences were noted in other contexts as well; Skladal et al. (2003b) documented that the age of presentation in Lebanese patients was significantly lower than in non-Lebanese patients and the minimum birth prevalence of respiratory chain disorders was 12-fold higher in this group. In the South African study, African patients predominantly (62.5%) had muscular involvement, with a distinct phenotype not observed in Caucasian patients; 30.0% presented with encephalomyopathy; and only 7.5% presented primarily with CNS involvement (Fig. 3a, b) . In addition, involvement of a CII+III deficiency was evident and statistically significant, and although it was not measured in the tissue, an underlying coenzyme Q deficiency may be a possibility. The contribution of mitochondrial DNA haplogroups in the expression of mitochondria-related disorders is often described (Brown et al. 2002; Khusnutdinova et al. 2008; Herrnstadt and Howell 2004) , and thus, along with other genetic factors, diet or lifestyle may also contributed to the differences in phenotypic expression among these diverse patients. Caucasian patients presented with an encephalomyopathic phenotype in 60.0% of cases, 20.0% had pure CNS involvement, and in the older patient group exercise intolerance with unexplained myalgia was prominent (Fig. 3b) . Patients were recruited from the pediatric neurology clinic, which explained the bias toward the neuromuscular presentation of mitochondrial disorders and the limited number of older patients. Patients might also have been missed owing to strict inclusion criteria for a muscle biopsy. The calculated MDC score might have resulted in underscoring, as limited histology was available. Furthermore, criteria to define a deficiency were relatively strict, as a deficiency expressed against two markers was required.
The frequency of hearing loss was comparable in the Austrian and South African studies, with 9.3% and 8.0%, respectively (Skladal et al. 2003a) . All South African patients with hearing impairment were Caucasian. The presence of altered muscle tone, including hypotonicity and/or hypertonicity, was present in 77.0% of Austrian patients (Skladal et al. 2003a ) and in 71.0% of the South African group.
Single enzyme deficiencies in the Caucasian group (60.0%) were more common than combined deficiencies, but combined deficiencies were found in 67.5% of African patients (Table 1 ; Fig. 4) . It is interesting to note that of the five patients identified as having a PDHc deficiency, only one was male. The Jaccard cluster analyses (Fig. 6) clearly illustrates that African patients tend to cluster together in terms of predominant myopathic involvement, and CII+III is mainly found in this group.
Mitochondrial syndromes were identified in 53.0% of cases in the Austrian study, which is considerably higher than in the American and Canadian studies, which reported this as 21.2% and 23.2%, respectively (Skladal et al. 2003a; Scaglia et al. 2004; Debray et al. 2007 ). Owing to a lack of mutation analyses, the South African study cannot be compared in this regard. 
Conclusion
Phenotypes of mitochondrial disorders in the South African population have been recognized by physicians in the past. Within a health system facing significant and wide-ranging challenges, as recently extensively reviewed by Lawn and Kinney (2009) , these disorders are mostly underdiagnosed. The calculated prevalence for this study, which served three provinces, is comparatively low (five to 20 times) considering the existing epidemiological data for developed countries and exposes the limitations of the existing capacity to diagnose these disorders in the South African population. The different groups of patients with mitochondriarelated neuromuscular disorders in South Africa have different phenotypes. African patients present predominantly with myopathy associated with CII+III deficiency, and Caucasian patients present predominantly with encephalopathy or encephalomyopathies. The confirmation of mitochondrial disorders in a developing country remains a challenge. A useful and simplified approach to enhancing awareness of mitochondrial disorders and prompt referral of patients in the South African scenario would be to consider a mitochondrial disorder in cases in which two or more seemingly unexplained and unrelated symptoms are observed (Munnich and Rustin 2001; Nissenkorn et al. 1999 ). In addition, biochemical and molecular genetic analyses for diagnosing these inherited metabolic disorders should be well coordinated in a country in which resources are limited and the burden of other, more pressing, health issues is increasing.
